BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 7 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2022. The put-call ratio across all filers is 3.11 and the average weighting 1.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,206,000 | +3.0% | 7,975 | -0.7% | 0.01% | +25.0% |
| Q2 2022 | $1,171,000 | -16.7% | 8,033 | -32.2% | 0.00% | +33.3% |
| Q1 2022 | $1,405,000 | -25.1% | 11,849 | -13.0% | 0.00% | -25.0% |
| Q4 2021 | $1,876,000 | +58.7% | 13,613 | +60.0% | 0.00% | +33.3% |
| Q3 2021 | $1,182,000 | -13.2% | 8,508 | -39.3% | 0.00% | -25.0% |
| Q2 2021 | $1,361,000 | +54.8% | 14,017 | +9.0% | 0.00% | +33.3% |
| Q1 2021 | $879,000 | -3.8% | 12,858 | +20.6% | 0.00% | 0.0% |
| Q4 2020 | $914,000 | +138.6% | 10,660 | +80.8% | 0.00% | +50.0% |
| Q3 2020 | $383,000 | -18.3% | 5,897 | -8.0% | 0.00% | -33.3% |
| Q2 2020 | $469,000 | +62.3% | 6,413 | +21.0% | 0.00% | +200.0% |
| Q4 2019 | $289,000 | – | 5,302 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
| Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
| ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
| DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
| Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
| Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |